Correlation between Cerebral Blood Volume Measurements by Perfusion-Weighted Magnetic Resonance Imaging and Two-Year Progression-Free Survival in Gliomas

Our goal was to determine whether relative cerebral blood volume (rCBV) can serve as an adjunct to histopathologic grading in the assessment of gliomas, with the hypothesis that rCBV can predict two-year survival. We evaluated 29 newly diagnosed gliomas (13 WHO grade II, seven grade III, nine grade TV; 17 astrocytomas, 12 oligodendroglial tumors). Dynamic susceptibility-weighted contrast-enhanced perfusion MR images and CBV maps were obtained. rCBVmax measurements (maximum tumor CBV/contralateral normal tissue CBV) and progression-free survival (PFS) were recorded. Receiver operating characteristic curves and Kaplan-Meier survival curves were calculated for rCBVmax and histologic grade. rCBVmax measurements differed between gliomas without (2.38 +/− 1.22) and with progression (5.57 +/− 2.84) over two years. The optimal rCBVmax cut-off value to predict progression was 2.95. rCBVmax < 2.95 was a significant predictor of two-year PFS, almost as accurate as WHO grade IT In the pure astrocytoma subgroup, the optimal rCBVmax cut-off value to predict progression was 2.85. In this group rCBVmax < 2.85 was a significant predictor of two-year PFS, an even better predictor of two-year PFS than WHO grade IT rCBVmax can be used to predict two-year PFS in patients with gliomas, independent of pathologic findings, especially in tumors without oligodendroglial components.

[1]  Michael H Lev,et al.  Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. , 2004, AJNR. American journal of neuroradiology.

[2]  Douglas C. Miller,et al.  Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. , 2008, Radiology.

[3]  A. Maia,et al.  MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. , 2005, AJNR. American journal of neuroradiology.

[4]  N. Probst-Hensch,et al.  Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas , 2004, Acta Neuropathologica.

[5]  T. Stadnik,et al.  Prognostic value of perfusion-weighted imaging in brain glioma: a prospective study , 2006, Acta Neurochirurgica.

[6]  S. Price,et al.  Advances in imaging low-grade gliomas. , 2010, Advances and technical standards in neurosurgery.

[7]  H. Mehdorn,et al.  Glioblastoma multiforme-report of 267 cases treated at a single institution. , 2005, Surgical neurology.

[8]  A. Alavi,et al.  Molecular imaging (PET) of brain tumors. , 2009, Neuroimaging clinics of North America.

[9]  A. Waldman,et al.  Low-grade gliomas: do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation? , 2008, Radiology.

[10]  A. Jackson,et al.  Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? , 2006, AJNR. American journal of neuroradiology.

[11]  T. Hirai,et al.  Prognostic Value of Perfusion MR Imaging of High-Grade Astrocytomas: Long-Term Follow-Up Study , 2008, American Journal of Neuroradiology.

[12]  P J Kelly,et al.  Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. , 1993, Journal of neurosurgery.

[13]  H. R. Arvinda,et al.  RETRACTED ARTICLE: Glioma grading: sensitivity, specificity, positive and negative predictive values of diffusion and perfusion imaging , 2009, Journal of Neuro-Oncology.

[14]  C. Maurage,et al.  Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma , 2007, Journal of Neuro-Oncology.

[15]  Gabriele Schackert,et al.  Long-term survival with glioblastoma multiforme. , 2007, Brain : a journal of neurology.

[16]  M Kirkpatrick,et al.  Cerebral Blood Volume Measurements by Perfusion-Weighted MR Imaging in Gliomas: Ready for Prime Time in Predicting Short-Term Outcome and Recurrent Disease? , 2009, American Journal of Neuroradiology.

[17]  G. Johnson,et al.  Relative cerebral blood volume measurements of low-grade gliomas predict patient outcome in a multi-institution setting. , 2010, European journal of radiology.

[18]  Glyn Johnson,et al.  Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. , 2003, AJNR. American journal of neuroradiology.

[19]  Z L Gokaslan,et al.  Limitations of stereotactic biopsy in the initial management of gliomas. , 2001, Neuro-oncology.

[20]  B. Rosen,et al.  Perfusion imaging with NMR contrast agents , 1990, Magnetic resonance in medicine.

[21]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[22]  Do-Hyun Nam,et al.  Prognostic significance of c‐Met expression in glioblastomas , 2009, Cancer.

[23]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Glyn Johnson,et al.  Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging--prediction of patient clinical response. , 2006, Radiology.

[25]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[26]  P. Kelly,et al.  Grading of astrocytomas: A simple and reproducible method , 1988, Cancer.

[27]  R. Makuch,et al.  Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas. , 1996, Neurosurgery.

[28]  Glyn Johnson,et al.  Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. , 2002, Radiology.

[29]  P. Warnke,et al.  Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours , 2006, Neuroradiology.

[30]  M Takahashi,et al.  Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. , 1998, AJR. American journal of roentgenology.

[31]  A. Karim,et al.  Prognostic factors for survival in adult patients with cerebral low-grade glioma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  J. Huse,et al.  Prediction of oligodendroglial tumor subtype and grade using perfusion weighted magnetic resonance imaging. , 2007, Journal of neurosurgery.